1. Patient who has participated in any other clinical trial of an experimental treatment for COVID-19 <br/ >2. Patients with the presence of any pre-existing illness that, in the opinion of the investigator, would place the patient at an unreasonably increased risk through participation in this study. <br/ >3. Patient who has participated in another trial with an investigational drug within 1 month prior to this trial. <br/ >4. Female patient who is breast-feeding, pregnant, or intends to become pregnant during the study <br/ >5. Patients who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol <br/ >

1. Patient who has participated in any other clinical trial of an experimental treatment for COVID-19 <br/ >2. Patients with the presence of any pre-existing illness that, in the opinion of the investigator, would place the patient at an unreasonably increased risk through participation in this study. <br/ >3. Patient who has participated in another trial with an investigational drug within 1 month prior to this trial. <br/ >4. Female patient who is breast-feeding, pregnant, or intends to become pregnant during the study <br/ >5. Patients who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol <br/ >

N/A

N/A

1. Patient who has participated in any other clinical trial of an experimental treatment for COVID-19 <br/ >2. Patients with the presence of any pre-existing illness that, in the opinion of the investigator, would place the patient at an unreasonably increased risk through participation in this study. <br/ >3. Patient who has participated in another trial with an investigational drug within 1 month prior to this trial. <br/ >4. Female patient who is breast-feeding, pregnant, or intends to become pregnant during the study <br/ >5. Patients who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol <br/ >

1. Patient who has participated in any other clinical trial of an experimental treatment for COVID-19 <br/ >2. Patients with the presence of any pre-existing illness that, in the opinion of the investigator, would place the patient at an unreasonably increased risk through participation in this study. <br/ >3. Patient who has participated in another trial with an investigational drug within 1 month prior to this trial. <br/ >4. Female patient who is breast-feeding, pregnant, or intends to become pregnant during the study <br/ >5. Patients who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol <br/ >